Risperidone News and Research

RSS
New report finds little evidence to support off-label use of atypical antipsychotics

New report finds little evidence to support off-label use of atypical antipsychotics

Benefits and harms vary among atypical antipsychotics for off-label use

Benefits and harms vary among atypical antipsychotics for off-label use

BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR

BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR

Risperidone does not appear to reduce military-related PTSD symptoms

Risperidone does not appear to reduce military-related PTSD symptoms

Post-traumatic stress disorder drug risperidone not working: Study

Post-traumatic stress disorder drug risperidone not working: Study

Young investigators to receive Brain & Behavior Research Foundation awards

Young investigators to receive Brain & Behavior Research Foundation awards

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

Risperidone recall by J&J

Risperidone recall by J&J

Study: Early intervention can reduce recurrences, prevent psychosis

Study: Early intervention can reduce recurrences, prevent psychosis

Mylan introduces Risperidone Orally Disintegrating Tablets for schizophrenia treatment

Mylan introduces Risperidone Orally Disintegrating Tablets for schizophrenia treatment

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

More studies needed to identify which specific autism treatments are helpful for specific children

More studies needed to identify which specific autism treatments are helpful for specific children

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

Children with ASDs benefit from certain medical and behavioral treatments

Children with ASDs benefit from certain medical and behavioral treatments

EDT receives European approval for XEPLION injection to treat schizophrenia

EDT receives European approval for XEPLION injection to treat schizophrenia

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

SureGene collaborates with Medco Health Solutions to conduct REST study

SureGene collaborates with Medco Health Solutions to conduct REST study

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Psychotropic medications common among children with ASD: Research

Psychotropic medications common among children with ASD: Research